Assisting Patients with Opioid Use Disorder (OUD) Treatment: Identification and Treatment

Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FASAM, FACPM

ACTIVITY DISCLAIMER

The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.

The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.
DISCLOSURE

It is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.

All individuals in a position to control content for this session have indicated they have no relevant financial relationships to disclose.

The content of my material/presentation in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FASAM, FACPM

Director, Center for Addiction Research and Effective Solutions (AIR), American Institutes for Research (AIR), Chicago, Illinois; Assistant Professor, Department of Family Medicine & Department of Psychiatry Section of Population Behavioral Health, Rush University Medical Center, Chicago, Illinois

Dr. Salisbury-Afshar is board-certified in family medicine, general preventive medicine/public health, and addiction medicine. She earned her medical degree from Rush Medical College in Chicago, Illinois, and her Master of Public Health (MPH) degree from Johns Hopkins University in Baltimore, Maryland. She completed a family medicine residency at the University of Illinois-Chicago/Illinois Masonic Medical Center and a residency in preventive medicine at Johns Hopkins University. Since graduating from family medicine residency in 2010, Dr. Salisbury-Afshar has continuously worked in federally qualified health centers (FQHCs) in both Baltimore and Chicago. Her role at the American Institutes for Research (AIR) focuses on public health and systems solutions to the opioid overdose crisis, and she also continues to work clinically on a part-time basis at Heartland Alliance Health, a health care for the homeless provider in Chicago. Her clinical focus is working with medically underserved populations, with a specific focus on integration of behavioral and physical health.
Learning Objectives

1. Describe the DSM 5 terminology and diagnostic criteria for opioid use disorder.
2. Name the three medications that are FDA approved for treatment of opioid use disorder.
3. Engage patients in shared decision making that includes treatment options and the evidence for each option.
4. Be prepared to initiate treatment or facilitate referrals.

Audience Engagement System
Agenda

- Background on the opioid crisis
- Identifying opioid use disorder in clinical setting
- Discussing treatment options
- Next steps

Background
Drug Overdose Deaths in United States, 1999–2017

Opioid Overdose Deaths (by type) 1999 to 2017

Source: https://www.cdc.gov/drugoverdose/images/epidemic/3WavesOfTheRiseInOpioidOverdoseDeaths.png

Public Health Interventions to Address Opioid Crisis

**Prevention**
- Prescribing limits
- Patient education
- Provider education
- Disposal of unused opioids

**Reducing Misuse**
- Drug (re)formulation
- Insurance utilization
- Pain clinic regulations
- Prescription drug monitoring programs

**Treatment and Recovery**
- Insurance coverage of medications for addiction treatment (MATs)
- MAT patient limits
- More waivered prescribers
- MATs in jails and prisons

**Harm Reduction**
- Naloxone access
- Good Samaritan laws
- Syringe access
- Overdose prevention sites

---

**Epidemic of Poor Access to Care**

Nearly 80% of Americans with opioid use disorder (OUD) don’t receive treatment.

There are not enough psychiatrists and addiction medicine specialists to address the demand.

Similar to the HIV crisis in the 1990s, primary care physicians can do this work well.

OUD treatment fits into medical home model.

AES Question 1

Which of the following describes the substance use services you currently offer?

A. I do not have a waiver to prescribe buprenorphine.
B. I have a waiver to prescribe buprenorphine but have never prescribed it.
C. I have a waiver to prescribe buprenorphine, and I have prescribed it in past but do not currently.
D. I have a waiver and actively prescribe buprenorphine.
Joe is a 53-year-old man who works in construction. He comes to your office and explains he’s looking for a new primary care physician because his primary care physician retired.

- History of work-related injury 4 years ago causing low back pain.
- Taking hydrocodone/acetaminophen 10/325 four times a day for the past 4 years (confirmed by checking PDMP). Reports this dose allows him to control his pain and continue to work.
- In-office urine drug screen shows presence of only hydrocodone and no other substances.

AES Question 2

Does Joe have opioid use disorder?

A. Definitely yes.
B. Probably yes.
C. Unsure; there is not enough information to make a diagnosis.
D. Probably not.
E. Definitely not.
What questions would you ask Joe to help you determine whether he might have opioid use disorder?

What Is Substance Use Disorder (SUD)?

• Many people use drugs and alcohol, but not all people develop substance or alcohol use disorder.
• Substance use disorder is not simply about the use of drugs; it is about the behaviors and symptoms around the use of drugs.
• Many people get better without formal treatment.
  – Treatment shortens the time it takes to get better.
  – Treatment reduces negative outcomes along the way (HIV, mental illness, overdose death).
Who Develops Substance Use Disorders?

- Genetic component
- Environmental component
- Behavioral component
- Early exposures associated with increased risk
  - Adverse childhood experiences
  - Early exposure to drugs and alcohol


Screening for Opioid Misuse

- SAMHSA recommends universal alcohol, tobacco, prescribed and illicit drug misuse screening annually in general medical practices.
- USPSTF “I” (insufficient evidence) recommends screening for illicit drug use in adults, adolescents, or pregnant women (update happening now).

Screening Instruments

• Numerous validated screening tools are available.
• Single-item screening is often used in primary care settings.

  – “How many times in the past year have you used an illegal drug or a prescription medication for nonmedical reasons?” (A positive screen is 1 or more days.)
  – A positive response leads to full Drug Abuse Screening Test (DAST-10).

Source: [https://www.drugabuse.gov/nidamed‐medical‐health‐professionals/screening‐tools‐resources/chart‐screening‐tools](https://www.drugabuse.gov/nidamed‐medical‐health‐professionals/screening‐tools‐resources/chart‐screening‐tools)

DAST-10

• Validated screening instrument
• Can be used for any drug
• Can be administered by either provider or patient

# Opioid Use Disorder Diagnosis

<table>
<thead>
<tr>
<th>Diagnostic and Statistical Manual of Mental Disorders 5 Criteria</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. More or longer than intended</td>
<td>Loss of control</td>
</tr>
<tr>
<td>2. Unable to cut back or control</td>
<td>Continued use despite consequences</td>
</tr>
<tr>
<td>3. Time dedicated to obtaining, using, recovering from</td>
<td>Craving or compulsion</td>
</tr>
<tr>
<td>4. Physical or psychological consequences</td>
<td></td>
</tr>
<tr>
<td>5. Activities given up</td>
<td></td>
</tr>
<tr>
<td>6. Failure to fulfill major obligations (work, school or home)</td>
<td></td>
</tr>
<tr>
<td>7. Continued use despite social or interpersonal problems caused or made worse</td>
<td></td>
</tr>
<tr>
<td>8. Recurrent use in hazardous situation</td>
<td></td>
</tr>
<tr>
<td>9. Craving, strong desire, or urge</td>
<td></td>
</tr>
<tr>
<td>10. Tolerance (unless taken solely under appropriate medical supervision)</td>
<td></td>
</tr>
<tr>
<td>11. Withdrawal (unless taken solely under appropriate medical supervision)</td>
<td></td>
</tr>
</tbody>
</table>

Severity is based on number of symptoms: **Mild** 2–3 symptoms, **Moderate** 4–5 symptoms, **Severe** ≥6 symptoms.


---

# Does Language Matter?

- A randomized controlled trial was held with mental health professionals.
- Two groups were given same clinical scenario: one with a “substance abuser” and the other with a “person with substance use disorder.”
- Those in the “substance abuser” condition agreed more with the notion that the character was personally culpable and that punitive measures should be taken.
- DSM IV terms of “dependence” and “abuse” were changed to “use disorders” in transition to DSM 5.

Language Matters

<table>
<thead>
<tr>
<th>Terms to avoid using</th>
<th>Terms to use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Addict, junkie, drug abuser</td>
<td>Person who uses drugs or person with substance use disorder</td>
</tr>
<tr>
<td>Substance abuse</td>
<td>Substance misuse or Substance use disorder</td>
</tr>
<tr>
<td>Clean (drug test)</td>
<td>Negative drug test</td>
</tr>
<tr>
<td>Dirty (urine drug test)</td>
<td>Positive drug test</td>
</tr>
<tr>
<td>Drug habit</td>
<td>Substance misuse, substance use disorder</td>
</tr>
<tr>
<td>Staying clean</td>
<td>In recovery/in remission</td>
</tr>
</tbody>
</table>

Source: https://www.addictionpolicy.org/blog/language-matters-infographic

Possible Questions for Joe

1. Any sense of **loss of control** around taking the medication?
2. Any negative **consequence** related to use of the medications?
3. Strong **cravings** when he doesn’t take his dose on time?
Possible Questions for Joe

4. Questions about possible risk factors for OUD:
   - Is there personal history of alcohol or drug use?
   - Any family history of alcohol or drug use?
   - Any history of depression or other mental illness?
   - Any history of adverse childhood events?

Joe’s Case: Option 1

• Joe denies any symptoms related to loss of control around his opioid use.
• He denies negative family or work consequences related to the opioid use.
• He denies experiencing cravings for the medication, but he does report feeling like he has flu symptoms when he misses too many doses.
• He denies a personal history of alcohol or substance use disorders.
• He has a remote history of depression but denies symptoms at this time.
AES Question 3

Does Joe have opioid use disorder?
A. Definitely yes.
B. Probably yes.
C. Unsure; there is not enough information to make diagnosis.
D. Probably not.
E. Definitely not.

Joe’s Case: Option 2

• Joe reports that he spends much of his day thinking about when he can take the next pill.
• He says that he doesn’t think he’s getting enough medication because he sometimes has to buy additional pills from someone at work because he runs out of his prescription early.
• He reports he’s had to miss some family events because he’s run out of medication early and feels too sick to attend.
• He reports that he had some problems with alcohol misuse when he was younger, but he denies current issues.
• His PHQ-9 score is 10 (moderate depression is 10–14), currently untreated.
AES Question 4

Does Joe have opioid use disorder?
A. Definitely yes.
B. Probably yes.
C. Unsure; there is not enough information to make diagnosis.
D. Probably not.
E. Definitely not.

Treatment for OUD
Substance Use Disorder Treatment

**Acute Care Model**
- Enter treatment
- Complete assessment
- Receive treatment
- Discharge

**Chronic Care Model**
- Prevention
- Early intervention
- Treatment
- Recovery support services


What Does SUD Treatment Look Like?

- Different levels of care
  - The level of care should be based on severity of disease and psychosocial situation.
  - The level of care can vary from 2 hours per week to intensive in-patient programs.
- Treatment may or may not include medications.
  - Not all substance use disorders have medications available to be part of treatment.
AES Question 5

Which of the following medications is NOT FDA approved for the treatment of opioid use disorder?

A. Buprenorphine.
B. Methadone.
C. Naloxone.
D. Naltrexone.

OUD Treatment

• Behavioral support
• Medication for addiction treatment (MAT)
  – Methadone
  – Buprenorphine (Suboxone®, Bunavail™, Zubsolve®, Subutex, Probuphine® implant, Sublocade injection)
  – Injectable extended release (ER) naltrexone (Vivitrol®)
• Approximately 1/3 of treatment providers offer methadone or buprenorphine.¹
• Detox is not a treatment and actually increases risk of overdose without linkage to next level of care.²

OUD Treatment

OUD medications have been shown to

- Reduce illicit opioid use,
- Retain people in treatment, and
- Reduce risk of opioid overdose death better than treatment with placebo or no medication.
- “Discussing medications that can treat OUD with patients who have this disorder is the clinical standard of care.”


MAT for OUD

- All three of the medications do two things:
  - Help control cravings (block negative reinforcement)
  - Reduce the experience of using opioids on top of the medication (block positive reinforcement)
- Pharmacology of the medications is different.
- Regulation around each medication is different.
- The availability of evidence is different.

MAT for OUD: Pharmacology

- Methadone
  - Full opioid agonist
  - Relieves withdrawal symptoms at lower doses (30–40 mg)
  - Provides opioid blockade at higher doses (>60 mg)
- Buprenorphine (Suboxone®, Bunavail™, Zubsolve®, Subutex, Probuphine® implant, Sublocade injection)
  - Partial opioid agonist (has ceiling effect; safer for overdose risk)
  - Relieves withdrawal symptoms at lower doses (4–8 mg)
  - Provides opioid blockade at higher doses (12–24 mg)
- Injectable extended-release (XR) naltrexone (Vivitrol®)
  - Opioid antagonist
  - Precipitates withdrawal symptoms; must have been without opioids for 10–14 days
  - Provides opioid blockade (28 days)

Opioid Agonists and Antagonists

Image used with permission of ASAM. Reproduced from content in the ASAM Buprenorphine Course by the American Society of Addiction Medicine.
Natural History of Opioid Use Disorder

Image used with permission of ASAM. Reproduced from content in the ASAM Buprenorphine Course by the American Society of Addiction Medicine.
Alford DP. http://www.bumc.bu.edu/care/

Opioid Agonist Therapy

Image used with permission of ASAM. Reproduced from content in the ASAM Buprenorphine Course by the American Society of Addiction Medicine.
Alford DP. http://www.bumc.bu.edu/care/
Buprenorphine and Methadone for OUD: Physiologic Effects

- **Methadone and buprenorphine** are opioid agonists
- Methadone and buprenorphine help with pain.
- Methadone and buprenorphine help with withdrawal symptoms. (People **DO NOT** need to “detox” to start these medications.)
- Overdose risk
  - At high doses of methadone, overdose is possible.
  - Overdose with buprenorphine can happen in opioid-naïve individual or when mixed with other respiratory depressants; it is rare on its own.
  - Both medications have increased risk for overdose when mixed with other drugs or alcohol.

XR Naltrexone for OUD: Physiologic Effects

- Naltrexone is an opioid antagonist, so people must go through full withdrawal before they can get the injection.
  - Typically, 10–14 days of no opioid use is recommended.
  - If it is given too early, people will go into precipitated withdrawal.
- Opioids will not work when the injection is active in the body.
  - It lasts for approximately 28 days.
- Overdose risk
  - Overdose risk while on naltrexone is active is almost zero; after 28 days, the risk is higher because of reduced tolerance.
MAT for OUD: Regulatory Differences

Methadone
- It was approved for OUD treatment in the 1970s.
- In the United States, it is only available in certified opioid treatment programs with strict regulations around administration.
  - It requires observed dosing 6 days/week during first months of treatment.
  - Counseling must be available.
  - Wraparound services vary by site.


MAT for OUD: Regulatory Differences

Buprenorphine
- It is FDA approved for OUD since 2002 and can be prescribed in outpatient settings with a waiver (requires additional education).
- Initially only physicians, now nurse practitioners and physician assistants can prescribe it.
- Each prescriber has a patient limit at any given time (30, 100, 275).
- Counseling must be offered (on-site or via referral), but medication should not be withheld if the patient does not engage.
- List of waivered providers is on SAMHSA treatment finder (not comprehensive).

MAT for OUD: Regulatory Differences

- **Injectable XR naltrexone** (Vivitrol)
  - It has been FDA approved for relapse prevention since 2010.
  - No additional license, waiver, etc. is required.
  - No controlled substance license is required to prescribe it (i.e., anyone with prescribing authority can prescribe it).
- **Oral naltrexone** is available but has not been shown to improve outcomes for opioid use disorder; it is not recommended for OUD.


---

MAT for OUD: Treatment Outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Methadone</th>
<th>Buprenorphine</th>
<th>XR Naltrexone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased retention in treatment</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Reduced illicit opioid use</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Reduced risk of overdose death</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Reduced all-cause mortality</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Reduced HIV risk behaviors</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

Retention in Treatment at 12 Months With Reduced Illicit Drug Use

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment without medication</td>
<td>6%</td>
</tr>
<tr>
<td>XR Naltrexone(^a,b)</td>
<td>10–31%</td>
</tr>
<tr>
<td>Buprenorphine(^a)</td>
<td>60–90%</td>
</tr>
<tr>
<td>Methadone(^a)</td>
<td>74–80%</td>
</tr>
</tbody>
</table>

\(^a\) Based on a meta‐analysis of research studies, the rates of success are lower in real‐world settings.

\(^b\) Most XR Naltrexone studies were only 3–6 months; 12‐month registry study only had percentage discontinued due to meeting goals. The numbers presented here are different from the report referenced because these values were updated based on Jarvis et al.’s study.

Sources:
- California Health Care Foundation. Why health plans should go to the MAT in the fight against opioid addiction.

Duration of Treatment

- Longer length of treatment is associated with better outcomes (methadone and buprenorphine).
  - Patients should continue as long as they benefit and no contraindications.
- Data are limited for long‐term use of XR Naltrexone, but the current recommendation is that patients should continue as long as they benefit and want to continue.

Treatment Selection: Methadone, Buprenorphine or XR Naltrexone?

- Shared medical decision making
  - Patient preference and past experience
  - Ease of withdrawal/ability to abstain from opioids for at least 10 days (for injectable naltrexone)
  - Risk of overdose
  - Patients with occupations that do not allow agonist treatment (individuals operating heavy machinery, transportation drivers, physicians, pilots)

- Access to treatment
- XR Naltrexone not recommended during pregnancy

NEXT STEPS
Practice Recommendations

Communicating with patients
• Screen for opioid misuse.
• Use DSM 5 language (opioid use disorder).
• Talk to patients about treatment options, evidence base, and know where to refer locally.
• Prescribe buprenorphine in your own practice (get a DATA waiver and use it).

Search for services by location using SAMHSA Treatment Finder
DATA Waiver

1. Complete a SAMHSA-approved buprenorphine waiver training:
   a. American Academy of Addiction Psychiatry
   b. American Society of Addiction Medicine
   c. Providers Clinical Support System (PCSS) for MAT. Apply through DEA website to get the waiver.

2. Get your “X” DEA number.
3. Start prescribing!

Resources for Additional Information and Training

- SAMHSA Tip 63: Medications for Opioid Use Disorder
- PCSS (Provider Clinical Support System). This link offers many free archived and live webinars.
  https://pcssnow.org

Source: https://www.samhsa.gov/medication-assisted-treatment/training-resources/buprenorphine-physician-training
Additional Practice Recommendation

**Prescribe Naloxone!**

- Patients with history of overdose
- Patients on >50 MME of prescribed opioids
- Patients using illicit opioids
- Friends and family of individuals who use opioids (may depend on laws in your state)

[Image used with permission from www.PrescribetoPrevent.org]

Questions
Contact Information

Elizabeth Salisbury-Afshar, MD, MPH
Esalisbury@air.org